Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Completed
Study type
Observational
Enrollment
305actual
Sites
30
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-10 | actual | When the study began enrolling |
| Primary completion | 2026-04-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate to Severe Atopic Dermatitis
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants achieving a reduction in Eczema Area and Severity Index (EASI) of at least 75% at 6 months
measured Month 6
Percentage of participants achieving a reduction in EASI of at least 75% at 12 months
measured Month 12
Percentage of participants achieving a reduction in EASI of at least 75% at 18 months
measured Month 18
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed